Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Aprepitant for Patients Receiving Carboplatin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* No prior chemotherapy~* Confirmed malignancy, scheduled to receive carboplatin monotherapy, or carboplatin in combination with agents of minimal, low, or moderate emetic potential~* Laboratory parameters adequate for chemotherapy~Exclusion Criteria:~* Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 3 or 4~* Presence of nausea and vomiting or use of major antiemetic agents during the 24 hours before chemotherapy administration~* Patients receiving radiotherapy within 5 days prior to the carboplatin~* Pregnancy or lactation~* Known allergy to any of the 3 antiemetics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- low dose aprepitant or fosaprepitant (Type: EXPERIMENTAL): In addition to standard prophylactic antiemetics (Ondansetron 16mg and Dexamethasone 20mg) patients will be given aprepitant 125mg orally or 115mg fosaprepitant intravenously prior to the first cycle of carboplatin-based chemotherapy. No medications will be given afterwards

Based on this trial design, predict the completion outcome and termination type (if applicable).